Healthcare Industry News: REMICADE
News Release - January 13, 2021
EVOQ Therapeutics Announces a License And Collaboration Agreement with Amgen
ANN ARBOR, Mich., Jan. 13, 2021 -- (Healthcare Sales & Marketing Network) -- EVOQ Therapeutics today announced a license and collaboration agreement with Amgen for the discovery and development of novel drugs for autoimmune disorders. Under the terms of the agreement, Amgen and EVOQ will collaborate on preclinical development and Amgen will be responsible for clinical development and commercialization. In exchange for exclusive rights to selected autoimmune programs, Amgen will make upfront and milestone payments potentially totaling more than $240 million, as well as pay royalties on sales of resulting therapies. Amgen is a world leader in the treatment of autoimmune disorders, with a portfolio that includes both innovative medicines, including Otezla® and Enbrel®, and biosimilar products, such as AMGEVITA® (a biosimilar to Humira®) and AVSOLA® (a biosimilar to REMICADE®).EVOQ Therapeutics is a biopharmaceutical company focused on the discovery and development of drugs to treat patients afflicted with autoimmune diseases. EVOQ's technology platform utilizes a proprietary synthetic HDL NanoDisc that has been optimized to deliver antigens for recognition by the immune system.
www.evoqtherapeutics.com
Source: EVOQ Therapeutics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
